Marco Brusasco, MD, Dermatology Section Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126 Parma, Italy;
Acta Dermatovenerol Croat. 2023 Dec;31(3):160-161.
A 39-year-old Caucasian woman affected by Noonan Syndrome (NS) mutated in RAF1 was referred to us with itchy lesions on her limbs that had appeared two months earlier. Clinically, there were multiple umbilicated papules with a hyperkeratotic central plug, localized on the upper and lower limbs (Figure 1, a-b). The patient had no personal history of diabetes mellitus or chronic renal failure, but suffered from hypertrophic cardiomyopathy. Blood tests showed no abnormalities. On histological examination of a skin lesion, an ectatic hair follicle with a hyperkeratotic ostium was observed with fragments of hair, inflammatory cells, and epidermal perforation. A final diagnosis of Kyrle disease (KD) was established. The patient underwent narrowband UVB (NB-UVB) phototherapy with residual atrophic scars (Figure 1, c-d), but with a complete and long-lasting resolution of symptoms. KD belongs to perforating dermatoses (PD), a heterogeneous group of skin diseases characterized by the transepidermal elimination of dermal components. Despite the classification of PD still being under debate, four primary forms are traditionally recognized: reactive perforating collagenosis, elastosis perforans serpiginosum, perforating folliculitis, and KD (1). The typical skin manifestation of KD is an eruption of dome-shaped papules and nodules, with a whitish central keratotic plug, mainly localized on the extremities and the buttocks. Described by Kyrle in 1916, KD is frequently associated with systemic diseases, especially chronic renal failure and diabetes mellitus. Other associated conditions include chronic hepatic disease, internal malignancies, and congestive heart disease (1). Despite the absence of a consensus, the control of the underlying disease remains the first therapeutic target. Both topical (keratolytics, retinoids, and corticosteroids) and systemic treatments (corticosteroids, retinoids, antibiotics, and phototherapy) have been reported to control skin manifestations (2). In our experience, NB-UVB is an effective option as first-line therapy in case of diffuse lesions, both in KD and in other PD (3). NS is a relatively common RASopathy, a heterogenous group of genetic diseases characterized by a defect of the Ras-mitogen-activated protein kinase (Ras-MAPK) pathway, with an estimated prevalence of 1/1000-2500. PTPN11 is the most frequent mutated gene, accounting for 50% of cases, but more than ten genes have been identified as causing NS (4). Classical features include a distinctive facial dysmorphism, short stature, pulmonic stenosis, and other anomalies of different organs. The skin is commonly involved. Keratinization disorders and hair abnormalities such as keratosis pilaris, ulerythema ophryogenes, wavy or curly hair, and scarce scalp hair, are often described. Other cutaneous signs include easy bruising, skin hyperlaxity, multiple lentigines, and café-au-lait spots (5). To the best of our knowledge, no cases of KD in patients with NS have been previously reported to date. The exact etiopathogenesis of KD is not clear, but it has been hypothesized that systemic diseases, such as diabetes and chronic renal failure, can cause a deposit of substances or dermis alterations, which triggers the inflammatory process with subsequent transepidermal extrusion (1). In our patient, we ruled out all the causes commonly associated with KD. It is however possible that this manifestation could be a direct result of the patient's illness. Our patient suffered from diffuse keratosis pilaris, and an abnormal epidermal keratinization with a secondary inflammatory dermic response is among the suggested possible pathogenetic mechanisms of KD (1). On the other hand, the hyperlaxity and fragility of the skin typical of NS suggest the presence of altered connective tissue, which could trigger an abnormal keratinization and, subsequently, the transepidermal extrusion, as well as perforating elastosis, which is associated with genetic connective tissue diseases (1). Moreover, our patient suffered from a cardiac disease, another condition associated with KD (5). Although these explanations have their appeal, there is currently insufficient evidence of a link between KD and NS, and it will be necessary to collect additional data to confirm this hypothesis.
一位 39 岁的白人女性,患有诺南综合征(NS)突变 RAF1,因四肢出现瘙痒性皮损两个月而被转诊至我们医院。临床上,四肢存在多发性脐状丘疹,中央有角化栓,角化栓中央有脐状凹陷(图 1,a-b)。患者无糖尿病或慢性肾衰竭个人病史,但患有肥厚型心肌病。血液检查无异常。皮损组织病理学检查可见扩张的毛囊,角化过度的口部有毛发碎片、炎症细胞和表皮穿孔。最终诊断为 Kyrle 病(KD)。患者接受了窄谱 UVB(NB-UVB)光疗,皮损遗留萎缩性瘢痕(图 1,c-d),但症状完全且持久缓解。KD 属于穿孔性皮肤病(PD),这是一组具有不同临床表现的皮肤病,其特征是真皮成分经表皮排出。尽管 PD 的分类仍存在争议,但传统上仍公认有四种主要形式:反应性穿孔胶原病、弹性穿孔性匐行性弹性纤维松解症、穿孔性毛囊炎和 KD(1)。KD 的典型皮肤表现为半球形丘疹和结节性皮损,中央有角化栓,呈白色,主要局限于四肢和臀部。1916 年由 Kyrle 描述,KD 常与系统性疾病相关,特别是慢性肾衰竭和糖尿病。其他相关疾病包括慢性肝病、内部恶性肿瘤和充血性心力衰竭(1)。尽管尚未达成共识,但控制基础疾病仍然是治疗的首要目标。局部(角质松解剂、类维生素 A 和皮质类固醇)和全身治疗(皮质类固醇、类维生素 A、抗生素和光疗)已被报道可控制皮肤表现(2)。在我们的经验中,NB-UVB 是一种有效的一线治疗选择,适用于弥漫性皮损,无论是在 KD 还是其他 PD 中(3)。NS 是一种相对常见的 RASopathy,是一组具有不同临床表现的遗传疾病,其特征是 Ras-丝裂原活化蛋白激酶(Ras-MAPK)途径缺陷,估计患病率为 1/1000-2500。PTPN11 是最常见的突变基因,占 50%,但已经发现了 10 多个基因可导致 NS(4)。其典型特征包括独特的面部畸形、身材矮小、肺动脉瓣狭窄和其他不同器官的异常。皮肤常受累。角化障碍和毛发异常,如毛发角化病、ulerythema ophryogenes、卷曲或波浪状毛发、稀疏的头皮毛发,也经常被描述。其他皮肤表现包括易瘀伤、皮肤过度松弛、多发性雀斑和咖啡牛奶斑(5)。据我们所知,迄今为止,尚未有 NS 患者并发 KD 的病例报告。KD 的确切病因尚不清楚,但据推测,糖尿病和慢性肾衰竭等系统性疾病可能会导致物质沉积或真皮改变,从而引发炎症反应,随后经表皮排出(1)。在我们的患者中,我们排除了所有常见的 KD 相关病因。但是,这种表现也可能是患者疾病的直接结果。我们的患者患有弥漫性毛发角化病,表皮角化过度和继发性炎症性真皮反应可能是 KD 的潜在发病机制之一(1)。另一方面,NS 患者的皮肤具有松弛和脆弱的特点,这表明存在异常的结缔组织,这可能会引发异常的角化,随后经表皮排出,以及与遗传结缔组织疾病相关的穿孔性弹性纤维松解症(1)。此外,我们的患者还患有心脏病,这是另一种与 KD 相关的疾病(5)。尽管这些解释具有一定吸引力,但目前尚无足够证据表明 KD 与 NS 之间存在关联,需要收集更多数据来证实这一假说。